Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

890820P

Avanti

18:0 DAP

Avanti Research™ - A Croda Brand 890820P, powder

Synonym(s):

1,2-distearoyl-3-dimethylammonium-propane

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C41H81NO4
CAS Number:
121315-93-3
Molecular Weight:
652.09
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 25 mg (890820P-25mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 890820P

lipid type

transfection
cationic lipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H]C(CN(C)C)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O

InChI

1S/C41H81NO4/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-40(43)45-38-39(37-42(3)4)46-41(44)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h39H,5-38H2,1-4H3

InChI key

RVBUSVJSKGVQQS-UHFFFAOYSA-N

Application

1,2-distearoyl-3-dimethylammonium-propane (18:0 DAP) might be used to formulate lipid nanoparticles (LNPs) and to test its efficiency of packaging mRNA into an LNP. It might also be used in the preparation of “bubble liposomes” (BLs).

Biochem/physiol Actions

1,2-distearoyl-3-dimethylammonium-propane (18:0 DAP) is a cationic lipid and serves as a pH-sensitive transfection reagent.

Packaging

5 mL Clear Glass Sealed Ampule (890820P-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yoko Endo-Takahashi et al.
Biomaterials, 34(11), 2807-2813 (2013-01-25)
We have developed polyethyleneglycol (PEG)-modified liposomes (Bubble liposomes; BLs) that entrap ultrasound (US) contrast gas, and we have reported that the combination of BLs and US exposure was an effective tool for delivering pDNA and siRNA in vitro and in
Siddharth Patel et al.
Journal of controlled release : official journal of the Controlled Release Society, 303, 91-100 (2019-04-16)
Retinal gene therapy has had unprecedented success in generating treatments that can halt vision loss. However, immunogenic response and long-term toxicity with the use of viral vectors remain a concern. Non-viral vectors are relatively non-immunogenic, scalable platforms that have had

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service